Payers

Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.

Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.

Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.

Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.

Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.

This study compares the impact of the 3 different out-of-pocket maximums proposed in Congress and by the Medicare Payment Advisory Commission.

This retrospective study using administrative claims data examining health care resource utilization (HCRU) found that in the months before a diagnosis of eosinophilic esophagitis (EoE), other diseases were more commonly diagnosed.

Medicaid managed care utilization review data for mental health services were analyzed for the calendar years 2017 and 2018. These data indicate low rates of utilization review denials for both inpatient and outpatient mental health services.

The rise in popularity of genetic testing brings along a myriad of challenges ranging from concerns on data privacy to insurance coverage, but, when utilized correctly, it could mark a step forward for significant advancements in individual and population health.

Geoffrey Boyce, CEO of Array Behavioral Care, discusses Array AtHome’s telebehavioral health services, which are now available to approximately 5 million Humana Medicare Advantage members.

Incyte has become the latest company to pull an FDA filing following Gilead and Secura Bio, which both voluntarily withdrew therapies that had been granted accelerated approval but hadn’t completed confirmatory studies for full approval.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Experts discuss current trends in Medicare Advantage during the current annual enrollment period, best practices for communication, and gain clarity about the benefits and costs for both providers and beneficiaries.

Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.

Compared with the European Union, biosimilar use in the United States lags, and the US government, health systems, and medical associations all have a role to play.

The deadline to enroll in health insurance available through the Affordable Care Act on the federal exchange is Saturday, January 15.

The first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years launched in the United States in November 2021 after being approved in August 2020.

In a National Coverage Determination decision memo released Tuesday, CMS said it will gather public comment for 30 days about its plan to limit coverage for Alzheimer disease (AD) biologics that target plaque buildup in the brain to patients enrolled in certain clinical trials.